Health ❯ Pharmaceuticals

Drug Development

Clinical Trials Weight Loss Drugs Clinical Research Regulatory Affairs Oncology Obesity Treatments Market Competition Cancer Drugs Regulatory Approval Cancer Treatment Innovative Therapies Market Access Therapeutics Targeted Therapy Alzheimer's Disease Monoclonal Antibodies Respiratory Diseases Obesity Active Ingredients FDA Approval Weight-loss Drugs Prostate Cancer Antiviral Drugs Chemical Synthesis Research Institutions Targeted Therapies Market Dynamics AI in Healthcare Combination Therapy Weight Loss Medications Generic Drugs Antimalarial Drugs Diabetes Treatment Weight Loss Biotechnology New Treatments ALS Treatment Pain Management AI in Medicine Natural Products Orphan Drugs FDA Approvals Biologics Pain Relief AI Applications Antiparasitic Drugs Cancer Treatments Natural Compounds Injectable Medications Clinical Efficacy Research and Development Antibiotic Resistance AstraZeneca Alzheimer's Treatments Gene Therapy Biopharmaceuticals Animal Testing Therapies Novo Nordisk Chronic Diseases Vaccines Testing Procedures Antibiotics Tirzepatide Regulatory Challenges Drug Formulation Liver Disease Drugs Liver Condition Treatment GLP-1 Drugs Moderna Non-Antibiotic Medications Regulatory Issues Cancer Drug Design Eli Lilly Lifespan Extension Amyloid-Removing Drugs Nanotechnology Telomerase Inhibitors Long-acting Medications Protein Therapeutics Antibiotic Discovery Modified Release Formulation Epilepsy Treatment Compounding Pharmacy Stroke Prevention FDA Regulations Acetaminophen First-in-Class Medications Innovation in Medicine Vaccine Manufacturing RNA Interference Life-Saving Drugs Therapeutic Efficacy International Trade Molecular Therapy Clinical Studies Cardiovascular Drugs Coronary Health Quantum Computing Applications

Lilly and Innovent Forge Territory-Split Cancer and Immunology Alliance

The deal includes $350 million upfront with potential milestones totaling about $8.5 billion plus tiered royalties.

Vistagen Faces Federal Securities Class Action After Fasedienol Phase 3 Failure

Skye Bioscience Investors Face Friday Deadline in Securities Class Action Over Nimacimab Disclosures

Amgen Reports Year-Long Weight-Loss Maintenance With Monthly or Quarterly MariTide Dosing

Nvidia, Eli Lilly Commit Up to $1 Billion for Bay Area AI Drug Discovery Lab

GSK and Ionis Report Phase 3 Success for Hepatitis B Drug, Plan Q1 Filings

Amgen Buys Oxford Spinout Dark Blue Therapeutics for Up to $840 Million

FDA Approves Vanda’s Nereus, First New Motion Sickness Treatment in Over 40 Years

FDA Issues Complete Response Letter for Corcept’s Relacorilant in Cushing’s-Related Hypertension

Law Firms Urge Telix Investors as Jan. 9 Lead-Plaintiff Deadline Nears

Hagens Berman and Pomerantz Launch Probes Into Rezolute After Phase 3 Ersodetug Failure

Skye Bioscience Faces Investor Class Actions as Firms Court Shareholders Before Jan. 16 Deadline

Zydus to Commercialize FDA-Approved Interchangeable Lucentis Biosimilar NUFYMCO in U.S. Under Bioeq Deal

BioMarin to Acquire Amicus for $4.8 Billion in Cash

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

FDA Clears First New Oral Gonorrhea Antibiotics in Over 30 Years

Chai Discovery Raises $130 Million Series B at $1.3 Billion Valuation

FDA Grants National Priority Voucher to J&J’s Tecvayli–Darzalex Combo in Multiple Myeloma

MoonLake Immunotherapeutics Investors Face Lead‑Plaintiff Deadline in Securities Fraud Suits

First GLP‑1 Implant Trial for Obese Cats Begins With First Patient Dosed